Biosimilar Development News

1. Key Trends That Will Shaped The Immunology Market In The Last Decade, According To GlobalData 1/22/2020

   From an increase in sales of interleukin inhibitors to the prevalence of biosimilars, this decade has been an eventful one in the immunology industry.

2. First Mover To Game Changer’: Celltrion Announces 2020-2030 Strategy At The 38^th J.P. Morgan Healthcare Conference 1/16/2020

   Celltrion today announced the company’s vision for the next decade at the 38th Annual J.P. Morgan Healthcare Conference in San Francisco, USA.

3. New Infliximab Biosimilar Program Soars To 93% Utilization At Health New England 1/15/2020

   Health New England released data showcasing results from its medical pharmacy program focused on biosimilar management in collaboration with Magellan Rx Management.

4. Alvotech And JAMP Pharma Enter Into An Exclusive Partnership For The Commercialization Of Key Biosimilars In Canada 1/14/2020

   Our sister company Alvotech and JAMP Pharma have entered into an agreement for an exclusive partnership to supply and commercialize five leading biosimilar candidates in the Canadian market. The current market value of the branded sales for these biosimilars is estimated to exceed $2B annually.

5. JAMP Pharma Group Signs A Landmark Partnership Agreement For The Commercialization Of Five Biosimilar Medicines In Canada 1/14/2020

   Canadian pharmaceutical company JAMP Pharma Group has signed an exclusive agreement with global speciality biopharmaceutical company Alvotech for the Canadian commercial rights to five biosimilars.

6. Coherus Acquires Commercial Rights For Avastin® Biosimilar In The United States 1/13/2020

   Coherus BioSciences, Inc. (“Coherus” or the “Company”, Nasdaq: CHRS), today announced the Company has entered into a licensing agreement with Innovent Biologics, (Suzhou) Co., Ltd., (“Innovent”), a leading biopharmaceutical company headquartered in China, to commercialize Innovent’s biosimilar candidate to Avastin® (bevacizumab) in the United States and Canada.

7. Mundipharma Enters Partnership With Samsung Bioepis To Expand Biosimilars Into Hong Kong And Taiwan 1/12/2020

   Mundipharma today announced a partnership with Samsung Bioepis to commercialize Samsung Bioepis' first-wave biosimilar candidates in Taiwan and Hong Kong.

8. Bio-Thera Solutions Launches First Commercial Product, QLETLI, In China 1/10/2020

   Bio-Thera Solutions, Ltd., a fully-integrated pharmaceutical company, today announced that QLETLI (格乐立), a biosimilar to Humira (adalimumab), is now available in China.

9. Samsung Bioepis And AffaMed Therapeutics’ Eculizumab Biosimilar Candidate Receives China IND Approval, Expanding The Ongoing Global Phase 3 Trial 1/10/2020

   Samsung Bioepis Co., Ltd. and AffaMed Therapeutics today announced that the China National Medical Products Administration (NMPA) has approved the Clinical Trial Application (CTA) for SB12, also referred to as AMT904 in China – a biosimilar candidate referencing Soliris® (eculizumab).

10. Sorrento Announces Filing For Approval Of Infliximab Biobetter Antibody By Its Partner Mabpharm In China 1/7/2020

    Sorrento Therapeutics (Nasdaq: SRNE) announced today that its partner Mabpharm (HK:2181) filed recently a New Drug Application for the Infliximab biosimilar antibody in China. Sorrento plans to file a Biologics License Application (BLA) for the Infliximab biobetter antibody in the United States in 2020.